Mi­cro­cap biotech Ocera craters on a PhI­Ib fail­ure for he­pat­ic en­cephalopa­thy

Ocera $OCRX has joined the grow­ing line­up of mi­cro­cap biotechs to ex­pe­ri­ence the crush­ing ef­fect of a clin­i­cal set­back. The biotech an­nounced that its lead, and on­ly, drug — or­nithine pheny­lac­etate (OCR-002) — failed a Phase IIb tri­al among hos­pi­tal­ized pa­tients suf­fer­ing from he­pat­ic en­cephalopa­thy.

There was a 17-hour re­duc­tion in time to an im­prove­ment in HE symp­toms, com­pared to the place­bo arm. But that was not sta­tis­ti­cal­ly sig­nif­i­cant and un­der­whelmed the an­a­lysts fol­low­ing this com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.